Contrasting HedgePath Pharmaceuticals (OTCMKTS:HPPI) and Medpace (OTCMKTS:MEDP)

Share on StockTwits

HedgePath Pharmaceuticals (OTCMKTS:HPPI) and Medpace (NASDAQ:MEDP) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.

Risk & Volatility

HedgePath Pharmaceuticals has a beta of -1.16, suggesting that its stock price is 216% less volatile than the S&P 500. Comparatively, Medpace has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500.

Insider and Institutional Ownership

77.0% of Medpace shares are owned by institutional investors. 4.8% of HedgePath Pharmaceuticals shares are owned by company insiders. Comparatively, 24.2% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares HedgePath Pharmaceuticals and Medpace’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
HedgePath Pharmaceuticals N/A N/A -$4.55 million N/A N/A
Medpace $704.59 million 4.03 $73.18 million $2.59 30.50

Medpace has higher revenue and earnings than HedgePath Pharmaceuticals.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for HedgePath Pharmaceuticals and Medpace, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HedgePath Pharmaceuticals 0 0 0 0 N/A
Medpace 0 1 3 0 2.75

Medpace has a consensus price target of $74.67, suggesting a potential downside of 5.49%. Given Medpace’s higher possible upside, analysts plainly believe Medpace is more favorable than HedgePath Pharmaceuticals.


This table compares HedgePath Pharmaceuticals and Medpace’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
HedgePath Pharmaceuticals N/A N/A -246.03%
Medpace 11.28% 17.65% 10.88%


Medpace beats HedgePath Pharmaceuticals on 10 of the 10 factors compared between the two stocks.

About HedgePath Pharmaceuticals

HedgePath Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers and non-cancerous proliferation disorders in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It also develops super bioavailability (SUBA)-itraconazole oral capsules for patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida. HedgePath Pharmaceuticals, Inc. is a subsidiary of Mayne Pharma Ventures Pty Ltd.

About Medpace

Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its drug development services include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.

Receive News & Ratings for HedgePath Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HedgePath Pharmaceuticals and related companies with's FREE daily email newsletter.